Solanezumab ‘fails’ in Alzheimer’s at last

Hate to say ‘we told you so’ all along!

Julian, Bengt and I said so in our review article last year.

There’s no substitute for the good old fashioned ordered process of clinical development – Learn first (Phase II) then Confirm (Phase III)

Biogen (aducanumab) next?

>>>>

http://www.fiercebiotech.com/biotech/alzheimer-s-hopes-dashed-as-lilly-gives-up-amyloid-drug-solanezumab?utm_medium=nl&utm_source=internal&mrkid=938224&mkt_tok=eyJpIjoiWVdNMVltTXlPR1kyWlRjdyIsInQiOiI1NGFBR2dHK1BNXC9GRmkxdVVcL3I5K2I3dEtiVWkwbXppbTdPdmhpQkJlRFwvK1dvK0lmYmt4a25WZVRhbWJQd1NQQ3ZibkZJWlwvUzJzZ1Njck9hXC9qVGd3M0ptZFZmVVduZVBNRnFyVHhIR0xJPSJ9